(NASDAQ: SEPN) Septerna's forecast annual revenue growth rate of -3.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Septerna's revenue in 2026 is $72,255,000.On average, 10 Wall Street analysts forecast SEPN's revenue for 2026 to be $3,396,576,638, with the lowest SEPN revenue forecast at $0, and the highest SEPN revenue forecast at $6,105,480,945. On average, 10 Wall Street analysts forecast SEPN's revenue for 2027 to be $3,094,255,038, with the lowest SEPN revenue forecast at $0, and the highest SEPN revenue forecast at $5,821,505,087.
In 2028, SEPN is forecast to generate $2,931,487,289 in revenue, with the lowest revenue forecast at $1,546,090,782 and the highest revenue forecast at $3,786,344,772.